Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

IGM Biosciences Inc

IGMS
Current price
6.22 USD -0.53 USD (-7.79%)
Last closed 6.74 USD
Company igmbio.com
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 311 240 544 USD
Yield for 12 month -69.00 %
Week
Month
Year
IGMS
21.11.2021 - 28.11.2021

IGM Biosciences, Inc., a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's product candidate, including imvotamab (IGM-2323), an IgM-based CD20 x CD3 bispecific antibody T cell engager that is in Phase 2 clinical trials for the treatment of B cell non-Hodgkin's lymphoma (NHL). It is also developing IGM-8444, an IgM antibody, which is in Phase 1a/1b clinical trials for the treatment of patients with solid cancers; and IGM-7354, an anti-PD-L1 IgM antibody that is in Phase 1 clinical trials for the treatment of patients with solid and hematologic malignancies; IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of patients with multiple myeloma; and IGM-2537, a bispecific T cell engaging IgM antibody targeting CD123 and CD3 proteins for the treatment of patients with acute myeloid leukemia, myelodysplastic syndromes, and acute lymphoblastic leukemia. IGM Biosciences, Inc. has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California. Address: 325 East Middlefield Road, Mountain View, CA, United States, 94043

Analytics

WallStreet Target Price

20.6 USD

P/E ratio

Dividend Yield

Current Year

+1 069 000 USD

Last Year

Current Quarter

+509 000 USD

Last Quarter

+448 000 USD

Current Year

+1 069 000 USD

Last Year

Current Quarter

+509 000 USD

Last Quarter

+448 000 USD

Key Figures IGMS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -246 612 000 USD
Operating Margin TTM -13115.91 %
PE Ratio
Return On Assets TTM -31.35 %
PEG Ratio
Return On Equity TTM -81.88 %
Wall Street Target Price 20.6 USD
Revenue TTM 1 851 000 USD
Book Value 4.35 USD
Revenue Per Share TTM 0.038 USD
Dividend Share
Quarterly Revenue Growth YOY 53.8 %
Dividend Yield
Gross Profit TTM 1 069 000 USD
Earnings Share -4.9 USD
Diluted Eps TTM -4.9 USD
Most Recent Quarter III 2023
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics IGMS

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History IGMS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation IGMS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 583.1817
Price Sales TTM 1136.7148
Enterprise Value EBITDA -1.8741
Price Book MRQ 2.5826

Financials IGMS

1 year
3 years
5 years
10 years
Results 2019 Dynamics

Technical indicators IGMS

For 52 weeks

3.81 USD 27.92 USD
50 Day MA 5.6 USD
Shares Short Prior Month 5 330 912
200 Day MA 10.67 USD
Short Ratio 14.32
Shares Short 4 998 739
Short Percent 32.98 %